News Aktuell

Agendia

20.06.2011 - 20:03

Agendia Postpones its IPO Due to Unfavourable Market Conditions

Amsterdam and Irvine, California (ots/PRNewswire) - - Not for release, distribution or publication in whole or in part, directly or indirectly, into or in the United States, Australia, Canada, OR Japan Agendia (or the "Company"), a commercial-stage ...weiter zur Meldung von Agendia

09.06.2011 - 08:02

Agendia Announces Colorectal Cancer Research Collaboration With Leading Cancer Centers - MD Anderson Cancer Center and Netherlands Cancer Institute

AMSTERDAM, The Netherlands, and IRVINE, California, June 9, 2011 (ots/PRNewswire) -- Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it has entered into a research collaboration with The University of Texas MD ...weiter zur Meldung von Agendia

06.06.2011 - 08:03

Agendia Announces Launch of Initial Public Offering (IPO) on NYSE Euronext in Amsterdam

Amsterdam (ots/PRNewswire) - - Agendia Publishes Prospectus and Sets Indicative IPO Price Range - Not for Release, Distribution or Publication in Whole or in Part, Directly or Indirectly, into or in The United States, Australia, Canada, or Japan ...weiter zur Meldung von Agendia

01.06.2011 - 08:02

Agendia Announces Six Studies in Breast and Colon Cancer for Presentation at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Amsteram and Irvine, California (ots/PRNewswire) - Agendia, a commercial-stage molecular cancer diagnostics company, announces today that it will present results from four completed and one ongoing study, at the Annual Meeting of the American ...weiter zur Meldung von Agendia

13.12.2008 - 16:40

Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients

Huntington Beach, California and Amsterdam (ots/PRNewswire) -- - Recent Study Reveals Substantial Group of Traditionally Miscategorized HER2+ Patients Dr. Michael Knauer from the Netherlands Cancer Institute today announced data ...weiter zur Meldung von Agendia

12.12.2008 - 15:45

Agendia's MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer

Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint(R)'s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura ...weiter zur Meldung von Agendia

08.12.2008 - 17:57

Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium

Huntington Beach, California and Amsterdam (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple ...weiter zur Meldung von Agendia

18.09.2008 - 14:05

Agendia's MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines

HUNTINGTON BEACH, California and AMSTERDAM, Netherlands, September 18 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint(R), has been ...weiter zur Meldung von Agendia